Novo Nordisk more than doubles sales target for obesity drugs on outlook for Wegovy

hapabapa/iStock Editorial via Getty Images

• Novo Nordisk (NVO) expects to generate over 25B Danish crowns ($3.72B) by 2025 from its obesity drug sales driven by the demand for the once-weekly GLP-1 receptor agonist Wegovy (semaglutide), Danish drugmaker said on Thursday at its capital markets day presentation.
• That was more than double the 2025 forecast set by the company in 2019 based on its other obesity medication, Saxenda (liraglutide), which raked in 6B Danish crowns that year.
• Saxenda and Wegovy generated sales worth 8.4B Danish crowns for the company in 2021. The initial demand for Wegovy led to supply constraints after its U.S. launch in June 2021.
• In December, Novo (NVO) ADRs slipped after the company cited manufacturing issues to indicate that it will not be able to meet the U.S. demand for the therapy in H1 2022.

Comments

[LiveFreeAZ]

Underestimates the obesity potential. 1. the new f/c is a conservative guess and 2. those who can't afford Wegovy are using Ozempic off-label which falls into the diabetes category. Bottom line is demand for this is crazy but you don't hear about it because nobody wants to admit using it. NVO below $115 is a big buy!

[Tetragrammaton]

Originally planned for release on Fat Tuesday, the news was delayed two days out of delicacy for patients’ feelings.